In addition to findings of the KEYNOTE 024 trial, results of the KEYNOTE 42 trial [6] which included any PD-L1 positive non-small cell lung cancer (NSCLC) patients led to the approval of pembrolizumab as the first-line single agent for the treatment of metastatic NSCLC. This evidence concerns the gene CD274 and non-small cell lung carcinoma.